Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 26, 2007. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than general financial performance.
Material Changes
A material change was reported regarding the US Retirement Savings Plan ("The Plan"). Following a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs, a decrease in the notional allocation was recorded on September 21, 2007.
- Transaction Date: September 21, 2007
- Price per ADR: $54.23
- Individual Involved: Mr. Russell Greig
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the impact of the notional allocation decrease on Mr. Russell Greig's total holdings.
- Confirm the current valuation of the US Retirement Savings Plan's notional investment in GSK Ordinary Share ADRs.
- Review the specific terms of the US Retirement Savings Plan regarding re-valuation triggers.